Management of JKN Medicine: The Role of Social Security Agency of Health (BPJS-K) in Strategic Health Purchasing

  • Yusi Anggriani Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta, 12460, Indonesia
  • Nurita Andayani Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta, 12460, Indonesia
  • Mawaddati Rahmi Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta, 12460, Indonesia
  • Rasta Naya Pratita Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta, 12460, Indonesia
  • Prih Sarnianto Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta, 12460, Indonesia
  • Atmiroseva Atmiroseva Social Security Agency of Health (BPJS-K)
  • Erfan Chandra Nugraha Social Security Agency of Health (BPJS-K)
  • Citra Jaya Social Security Agency of Health (BPJS-K)
DOI: https://doi.org/10.35814/jifi.v21i1.1371

Abstract

The National Health Insurance System (JKN) has social and equity insurance principles aiming participants receive basic health benefits. This raises must-have other requirements for circulated medicine, namely availability and accessibility. Thus, this must meet the elements of safety, efficacy/ benefits, good quality, market availability, and easy accessibility. However, drug shortages problem still occurs and ranks 3rd for BPJS Kesehatan services complaints. This study is to identify opportunities and constraints of BPJS in strategic health purchasing to increase access to JKN medicine . This is a crosssectional study using quantitative and qualitative methods. Quantitative research uses Structural Equation Modelling (SEM), while qualitative uses Focus Group Discussion (FGD). This found the problem roots related to JKN medicine shortages, including limited human resource capabilities, in optimal planning processes, e-purchasing method constraints, e-purchasing system and manual purchases medicine prices differences, medicines ordering long lead time, and in optimal BPJS Kesehatan role as a strategic health purchaser. Therefore, it is to increase BPJS Kesehatan’s role as an active purchaser by making an information system for all medicine use in JKN services, forming a Drugs Advisory Board/JKN drug working group and coordination between policy-making institutions to optimize BPJS Kesehatan role in ensuring JKN medicines access.

References

1. Ministry of Health, Peraturan Menteri Kesehatan Republik Indonesia Nomor 71 Tahun 2013 tentang Pelayanan Kesehatan pada Jaminan Kesehatan Nasional. 12 November 2013

2. Presiden Republik Indonesia. Peraturan Presiden Republik Indonesia Nomor 36 Tahun tentang Kesehatan. 13 Oktober 2009.

3. Ministry of Health, Peraturan Menteri Kesehatan Republik Indonesia Nomor 13 Tahun 2022 tentang Perubahan atas Peraturan Menteri Kesehatan Nomor 21 tahun 2020 tentang Rencana Strategis Kementerian Kesehatan tahun 2020-2024

4. Tim Nasional Percepatan Penanggunalangan Kemiskinan, Kajian Kebijakan Pengadaan Obat untuk Program Jaminan Kesehatan Nasional 2014-2018. 2020. Available from: https://www.tnp2k.go.id/download/29882Kajian%20Kebijakan%20Obat%202014-2018%2026%20Juni%202020%20(1).pdf

5. BPJS Kesehatan, Pelayanan Obat Luar Paket dalam Program JKN (Challenge & Oprtunity). In: Pertemuan Nasional Kepala Bidang PMR; 2022.

6. Selma Siahaan, Rini Sasanti Handayani. The identification of pharmaceutical practices that suited to need of patients and health care fasilities; 2019. Available from: http://dx.doi.org/10.22435/hsr.v22i2.285

7. Yusi Anggriani, Rina Rosdiana, Sondang Khairani. Evaluation of medicines planning and procurement in the era of national health insurance(jkn) in Health Center Cianjur District. In: Pharmacy:Pharmaceutical Journal of Indonesia, Vol.17 No.2 Desember 2020. Pg.425-438. Available from: https://media.neliti.com/media/publications/521978-none-48413035.pdf

8. Septi C.F.Hitto, Gayatri Citraningtyas, Imam Jayanto. Evaluation of availability of pharmacy installation of weda regional general hospital, Central Halmahera Regency. In: Pharmacon-FMIPA, Sam Ratulangi University, Vol.11 No. 2 Mei 2022. Pg.1467-1472. Available from: https://ejournal.unsrat.ac.id/v3/index.php/pharmacon/article/download/41737/37053/

9. Amalia Hasnida, Marten O Kok, Elizabeth Pisani. Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia. BMJ Global Health 2021;6:e003663. doi:10.1136/bmjgh-2020-003663

10. Budi Hidayat, Atik Nurwahyuni. Optimalisasi Strategic Purchasing BPJS Kesehatan. In: Ringkasan Riset JKN-KIS 2nd Edition September 2017.

11. Ministry of Health, Peraturan Menteri Kesehatan Republik Indonesia Nomor 58 Tahun 2014 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. 18 Agustus 2014

12. Ministry of Health, Peraturan Menteri Kesehatan Republik Indonesia Nomor 74 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Puskesmas. 23 Desember 2016

13. George Walukana, Shital Maru, Peter Karimi, Pierre Claver Kayumba. Effect of universal health coverage on the availability of medicines in public healthcare facilities in kisumu country, in kenya. Rwanda Journal of Medicine and Health Sciences Vol.4 No.2, August 2021. pg269-280. Available from: https://www.ajol.info/index.php/rjmhs/article/view/214249

14. Bizimana T, Kayumba PC, Heide L. Prices, availability, and affordability of medicines in Rwanda. PLoS ONE 15(8): e0236411. 2020. Available from: https://doi.org/10.1371/journal.pone.0236411

15. RI, Undang-Undang Republik Indonesia Nomor 24 Tahun 2011 tentang Badang Penyelenggaraan Jaminan Sosial, 2011
Published
2023-04-29
How to Cite
ANGGRIANI, Yusi et al. Management of JKN Medicine: The Role of Social Security Agency of Health (BPJS-K) in Strategic Health Purchasing. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 21, n. 1, p. 57-64, apr. 2023. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1371>. Date accessed: 24 nov. 2024. doi: https://doi.org/10.35814/jifi.v21i1.1371.
Citation Formats
Issue
Vol 21 No 1 (2023): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.